Rapid identification of extensively and extremely drug resistant tuberculosis from multidrug resistant strains; using PCR-RFLP and PCR-SSCP
,
Abstract
Background and Objectives: Resistance in Mycobacterium tuberculosis is caused by mutations in genes encoding drug targets. Investigators have already demonstrated the existence of mutations in codons 88 to 94 in the gyrA gene and also in codons 1400, 1401, and 1483 of rrs gene among extensively and extremely drug resistant tuberculosis (XDR & XXDR-TB) strains. The aim of this study was to identify the XDR and XXDR-TB stains based on their mutational analysis.
Materials and Methods: Susceptibility testing against first and second–line anti-tuberculosis drugs was performed by the proportional method. Based on susceptibility results, samples were later analyzed, using PCR-SSCP and PCR-RFLP for detection of mutation in gyrA and rrs genes.
Results: Overall, using proportional method, sixty-three strains (64.9%) were identified as MDR, 8(8.2%) as non-MDR and 26 strains (26.8%) were susceptible. Thirty-one cases (31.9%) were amikacin-resistant and 18 (18.5%) samples were ciprofloxacin-resistant. Using PCR-SSCP and PCR-RFLP, we identified 6(6.2%) and 7(7.2%) resistant strains, respectively. Discrepancy in strains was cross-checked by sequencing. The results showed no mutation in 66.6% and 77.4% of CIP and AMK- resistant strains.
Conclusion: Rapid detection of drug-resistant Mycobacterium tuberculosis using molecular techniques could be effective in determining therapeutic regimen and preventing the spread of XDR and MDR TB in the community. We should still keep in mind that a high number of resistant strains may have no mutation in proposed candidate genes.
Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro surveill 2007; 12: E070517.1.
Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug resistant tuberculosis bacilli: super extensively drug resistant tuberculosis or totally drug resistant strains in Iran. Chest 2009; 136: 420-425.
Farnia P, Masjedi MR, Merza MA, Tabarsi P, Zhavnerko GK, Ibrahim TA, et al. Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) tuberculosis strains: transmission and atomic force observation. Int J Clin Exp Med 2010; 3: 308-314.
Centers for Disease Control and Prevention (CDC).Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs worldwide,2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-305.
Lawn SD, Wilkinson R. Extensively drug resistant tuberculosis. BMJ 2006; 333: 559-560.
Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/ InfectiousDiseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis. Tuber Lung Dis 1998; 79: 3-29.
Pitaksajjakul P, Wongwit W, Punprasit W, Eampokalap B, Peacock S, Ramasoota P. Mutations in the gyrA and gyrB genes of Fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health 2005; 36 Suppl 4:228-237.
Suzuki Y, Katsukawa C, Tamaru A, Abe C, Makino M, Mizuguchi Y, et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying Mutations in the 16S rRNA Gene. J Clin Microbiol 1998; 36:1220-1225.
Kent PT, Kubica GP. Public health mycobacteriology: a guide for a level III laboratory. Atlanta, GA: Public Health Services, U.S 1985. Department of Health and Human Services, Centers for Disease Control, Atlanta, Ga.
World Health Organization (WHO). Guidelines for drug susceptibility testing for second-line anti- tuberculosis drugs for DOTS-plus. Geneva, Switzerland 2001; WHO/CDS/TB/2001. 288.pdf. Available from: http://whqlibdoc.who.int/hq/2001/WHO_CDS_ TB_2001.288.pdf. Accessed April 20, 2009.
Hosek J, Svastova P, Moravkova M, Pavlik I, Bartos M.Methods of mycobacterial DNA isolation from different biological material. Vet Med (Praha) 2006; 51: 180-192.
Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-780.
Kempsell KE, Ji YE, Estrada IC, Colston MJ, Cox RA. The nucleotide sequence of the promoter, 16S &RNA and spacer region of the ribosomal RNA operon of Mycobacterium tuberculosis and comparison with Mycobacterium leprae precursor rRNA. J Gen Microbiol 1992; 138: 1717-1727.
Lacoma A, Garcia-Sierra N, Prat C, Maldonado J , Ruiz- Manzano J, Haba L, et al. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2012; 50: 30-36.
Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 2032-2041.
Groll AV, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009; 53:4498-4500.
Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, Rüsch-Gerdes S, et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug- resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009; 53: 3353-3356.
Antonova OV, Gryadunov DA, Lapa SA, Kuzmin AV, Larionova EE, Smirnova TG, et al. Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridiza- tion on biological microchips. Bull Exp Biol Med 2008;145: 108-113.
Kocagoz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF. Gyrase mutations in laboratory-selected, fluoroquinolone resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40: 1768-1774.
Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148-1150.22. Taniguchi H, Chang B, Abe C, Nikaido Y, Mizuguchi Y, Yoshida SI. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system. J Bacteriol 1997; 179:4795-4801.
Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E, Riccardi G. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48:3175-178.
Victor TC, Van Helden PD, Warren R. Prediction of drug resistance in M. tuberculosis: molecular mechanisms, tools, and applications. IUBMB Life 2002; 53: 231-237.
| Files | ||
| Issue | Vol 4 No 4 (2012) | |
| Section | Articles | |
| Keywords | ||
| Mycobacterium tuberculosis PCR-RFLP PCR-SSCP amikacin ciprofloxacin | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
